### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

#### VERTEX PHARMACEUTICALS INC / MA

Form 4

December 16, 2004

Check this if no longer subject to Section 16. Form 4 or Form 5 obligations may continu See Instruct 1(b).	Filed pur Section 17(	Washington, D.C. 20549  STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  20(b) of the Investment Company Act of 1940									
	dress of Reporting	Symbo VER	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]				5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)				
C / C / C / C / Dute of Entire of Transportion							DirectorX Officer (give below)		Owner er (specify		
CAMBRIDGI	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)  CAMBRIDGE, MA 02139							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip) Ta	ble I - Non-I	Derivative	Secur	ities Acq	uired, Disposed of	f, or Beneficial	ly Owned		
	2. Transaction Date Month/Day/Year)	e 2A. Deemed Execution Date, i any (Month/Day/Yea	Code r) (Instr. 8)	4. Securion(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial		
Common Stock	12/15/2004		M	7,000	A	\$ 9.5	115,108	D			
Common Stock	12/15/2004		S(1)	7,000	D	\$ 11.32	108,108	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Stock

Common

8,084

I

401(k)

#### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

5. Number 6. Date Exercisable and

SEC 1474 (9-02)

7. Title and Amount of

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative	(Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Code Securities Day/Year) (Instr. 8) Acquired (A) or		Expiration Date (Month/Day/Year)		Underlying Securities (Instr. 3 and 4)	
	Security				Disposed of (D) (Instr. 3, 4, and 5)				
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 9.5	12/15/2004		M	7,000	03/14/1996(2)	12/13/2005	Common Stock	7,000

### **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

SATO VICKI L C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE, MA 02139

3. Transaction Date 3A. Deemed

President

## **Signatures**

1. Title of 2.

Valerie L. Andrews, Attorney-In-Fact

Date

12/16/2004

\*\*Signature of Reporting Person

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1.
- (2) Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2